ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b3 Clinical Trial for Patients with Sepsis - Yahoo Finance

ABNX Stock  EUR 1.22  0.01  0.83%   
About 52% of Abionyx Pharma's investor base is interested to short. The analysis of current outlook of investing in Abionyx Pharma SA suggests that many traders are impartial regarding Abionyx Pharma's prospects. The current market sentiment, together with Abionyx Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use Abionyx Pharma SA stock news signals to limit their universe of possible portfolio assets.
  
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b3 Clinical Trial for Patients with Sepsis Yahoo Finance

Read at news.google.com
Google News at Macroaxis
  

Abionyx Pharma Fundamental Analysis

We analyze Abionyx Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abionyx Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abionyx Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Z Score

Z Score Comparative Analysis

Abionyx Pharma is currently under evaluation in z score category among its peers. Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..

Abionyx Pharma SA Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Abionyx Pharma stock to make a market-neutral strategy. Peer analysis of Abionyx Pharma could also be used in its relative valuation, which is a method of valuing Abionyx Pharma by comparing valuation metrics with similar companies.

Complementary Tools for Abionyx Stock analysis

When running Abionyx Pharma's price analysis, check to measure Abionyx Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Abionyx Pharma is operating at the current time. Most of Abionyx Pharma's value examination focuses on studying past and present price action to predict the probability of Abionyx Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Abionyx Pharma's price. Additionally, you may evaluate how the addition of Abionyx Pharma to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
CEOs Directory
Screen CEOs from public companies around the world
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges